Atazanavir Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 370

Clinical Trials

Atazanavir has been evaluated in numerous Phase 1 through 4 clinical trials, encompassing completed, active, and terminated studies. Primarily targeting HIV-1 and AIDS alongside secondary conditions such as Hepatitis C, endotoxemia, sepsis, and HIV-associated lipodystrophy syndrome, these trials are sponsored by pharmaceutical companies like Bristol-Myers Squibb and academic partners such as the University of Liverpool and Radboud University Medical Center. Research across these studies focuses on assessing antiretroviral efficacy, pharmacokinetic profiles, dosage optimization, and metabolic safety.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02016924	ACTIVE_NOT_RECRUITING	Acquired Immune Deficiency Syndrome (AIDS); HIV Infections	Gilead Sciences	2014-01-16	PHASE2; PHASE3
NCT04022967	UNKNOWN	HIV-1-infection	ANRS, Emerging Infectious Diseases	2020-09-21	PHASE3
NCT04452565	UNKNOWN	Coronavirus Infection; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome Coronavirus 2	Biomed Industries, Inc.	2022-06-15	PHASE2; PHASE3
NCT05680792	COMPLETED	Drug Interaction	Obafemi Awolowo University	2020-09-10
NCT04184869	COMPLETED	Solid Tumor; Hematological Malignancies	Acrotech Biopharma Inc.	2019-08-05	PHASE1
NCT05236738	COMPLETED	Healthy Participants	Bristol-Myers Squibb	2022-05-13	PHASE1
NCT04121195	COMPLETED	HIV/AIDS; Tuberculosis	University of Liverpool	2020-10-30	PHASE2; PHASE3
NCT02307656	COMPLETED	HIV in Adults	Bristol-Myers Squibb	2014-12-12	PHASE1
NCT04468087	COMPLETED	COVID-19	Hospital do Coracao	2021-02-15	PHASE2; PHASE3
NCT04385719	COMPLETED	Ebola; HIV/AIDS	Makerere University	2021-05-05	PHASE2
NCT04459286	TERMINATED	Covid-19	Obafemi Awolowo University	2020-10-09	PHASE2
NCT04263350	COMPLETED	Healthy Participants	Bristol-Myers Squibb	2020-02-26	PHASE1
NCT04121195	Active not recruiting	HIV/AIDS\|Tuberculosis	University of Liverpool\|European and Developing Countries Clinical Trials Partnership (Funder)\|Joint Clinical Research Centre Kampala Uganda\|University of Cape Town Cape Town South Africa\|Infectious Diseases Institute Makerere University College of Health Sciences Kampala Uganda\|University of Turin Turin Italy	2020-10-30	Phase 2\|Phase 3
NCT04531072	COMPLETED	Drug Interaction	Fogarty International Center of the National Institute of Health	2018-09-18	PHASE4
NCT02652793	COMPLETED	Human Immunodeficiency Virus	Judit Pich	2015-11
NCT03708861	WITHDRAWN	HIV Infection	University of Turin, Italy	2016-01	PHASE3
NCT02473328	COMPLETED	HIV-1 Infection	Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	2015-06	PHASE2
NCT02697851	TERMINATED	HIV	St Stephens Aids Trust	2016-07	PHASE1
NCT02652624	COMPLETED	HIV-1 Infection	Gilead Sciences	2016-02-19	PHASE3
NCT01829802	UNKNOWN	Chronic Infection With HIV	Pedro Cahn	2014-05	PHASE4
NCT02116660	TERMINATED	HIV Infections	Merck Sharp & Dohme LLC	2014-09-03	PHASE2
NCT02386098	TERMINATED	HIV Infections	ViiV Healthcare	2015-07-08	PHASE2
NCT02603107	COMPLETED	HIV-1 Infection	Gilead Sciences	2015-11-20	PHASE3
NCT02566707	TERMINATED	HIV-1 Infection	Radboud University Medical Center	2015-08	PHASE2
NCT01902186	TERMINATED	HIV Infection; Osteopenia	Giovanni Di Perri	2014-09	PHASE4
NCT02697851	Terminated	HIV	St Stephens Aids Trust\|Bristol-Myers Squibb	2016-07	Phase 1
NCT02542852	COMPLETED	HIV-1 Infection	Castagna Antonella	2015-09	PHASE2
NCT01599364	COMPLETED	Human Immunodeficiency Virus	Catholic University of the Sacred Heart	2014-04	PHASE4
NCT02589158	COMPLETED	HIV	St Stephens Aids Trust	2015-11	PHASE1
NCT01003990	COMPLETED	HIV	Bristol-Myers Squibb	2002-10	PHASE3
NCT02246998	COMPLETED	HIV-1 Infection	Gilead Sciences	2014-12-15	PHASE4
NCT02565888	COMPLETED	Hepatitis C; HIV	Radboud University Medical Center	2015-11	PHASE1
NCT02154360	COMPLETED	HIV Infection	University of Pennsylvania	2014-05	PHASE1
NCT01367236	COMPLETED	HIV; Impaired Cognition	Imperial College London	2013-01	PHASE4
NCT01910402	COMPLETED	Infection, Human Immunodeficiency Virus; HIV Infections	ViiV Healthcare	2013-08-22	PHASE3
NCT03019783	COMPLETED	HIV	Brigham and Women's Hospital	2011-12	PHASE2; PHASE3
NCT01967940	COMPLETED	HIV; HIV Infections; Acquired Immunodeficiency Syndrome	Gilead Sciences	2013-10-25	PHASE3
NCT00074581	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	2005-02	PHASE3
NCT01705574	COMPLETED	Acquired Immunodeficiency Syndrome; HIV Infections	Gilead Sciences	2012-10-24	PHASE3
NCT01351740	COMPLETED	HIV Infection	University of British Columbia	2011-07	PHASE4
NCT02442700	COMPLETED	HIV; Dyslipidemia	Ramathibodi Hospital	2014-05	PHASE4
NCT01159223	COMPLETED	HIV Infections	The HIV Netherlands Australia Thailand Research Collaboration	2011-05	PHASE4
NCT01803074	COMPLETED	Infection, Human Immunodeficiency Virus; HIV Infections	ViiV Healthcare	2013-04-04	PHASE2
NCT02034838	COMPLETED	HIV Infection	Ottawa Hospital Research Institute	2014-01	PHASE1
NCT01691794	COMPLETED	HIV, Pediatric	Bristol-Myers Squibb	2012-11-30	PHASE4
NCT01335698	COMPLETED	HIV	Bristol-Myers Squibb	2011-05-27	PHASE3
NCT01605084	WITHDRAWN	HIV	Bristol-Myers Squibb	2012-06-30	PHASE3
NCT01307488	COMPLETED	HIV Infection	Fundacion SEIMC-GESIDA	2011-09	PHASE4
NCT02102048	UNKNOWN	HIV	University of Roma La Sapienza	2009-01
NCT01479361	COMPLETED	HIV; PCP; Toxoplasmosis	National Institutes of Health Clinical Center (CC)	2011-10-31	PHASE1
NCT01421355	COMPLETED	Type 1 Diabetes Mellitus	Brigham and Women's Hospital	2012-05	PHASE1
NCT01759875	COMPLETED	Healthy	University of California, San Francisco	2013-01	PHASE1
NCT00940771	COMPLETED	Pediatric HIV; HIV Infections	Phoenix Children's Hospital	2009-08-26	PHASE4
NCT01332227	COMPLETED	HIV, Combination Therapy	Bristol-Myers Squibb	2011-10	PHASE4
NCT01565889	COMPLETED	Hepatitis C; HIV	Gilead Sciences	2012-03	PHASE1; PHASE2
NCT01511809	COMPLETED	HIV-1 Infection	IRCCS San Raffaele	2010-09	PHASE3
NCT00491556	COMPLETED	HIV Infections	University of North Carolina, Chapel Hill	2007-10
NCT01837719	COMPLETED	Human Immunodeficiency Virus Type 1 (HIV-1)	Bristol-Myers Squibb	2013-04	PHASE1
NCT00811954	COMPLETED	HIV Infection	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	2009-05	PHASE3
NCT01274780	COMPLETED	HIV-1	Juan A. Arnaiz	2011-05	PHASE4
NCT00814879	COMPLETED	Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections	Yale University	2009-05
NCT01255371	WITHDRAWN	HIV	ANRS, Emerging Infectious Diseases	2012-03	PHASE3
NCT01818856	COMPLETED	Hepatitis C, Chronic; HIV Infection	Hospitales Universitarios Virgen del Rocío	2012-12	PHASE1
NCT00878306	COMPLETED	HIV Infections; Drug Abuse	University of California, San Francisco	2008-11	PHASE1
NCT01384734	COMPLETED	Infection, Human Immunodeficiency Virus	ViiV Healthcare	2011-07-26	PHASE2
NCT01656109	COMPLETED	HIV	The HIV Netherlands Australia Thailand Research Collaboration	2011-07	PHASE2
NCT01620944	TERMINATED	HIV	Bristol-Myers Squibb	2012-07-31	PHASE3
NCT01105611	UNKNOWN	HIV Infections; Hepatitis C	St. James's Hospital, Ireland	2010-08	PHASE4
NCT00540137	COMPLETED	HIV Infections	Imperial College London	2007-07	PHASE4
NCT00762892	COMPLETED	HIV Infections	The University of Texas Health Science Center, Houston	2009-01	PHASE4
NCT00532168	COMPLETED	HIV Infections	Juan A. Arnaiz	2007-09	PHASE4
NCT01099579	COMPLETED	HIV Infections	Bristol-Myers Squibb	2010-10-13	PHASE3
NCT01225705	WITHDRAWN	HIV; Hepatitis C	University Hospital, Bonn	2010-10	PHASE4
NCT01102972	COMPLETED	Infection, Human Immunodeficiency Virus	ViiV Healthcare	2010-04	PHASE4
NCT01592305	COMPLETED	Healthy Volunteer	Hoffmann-La Roche	2012-05	PHASE1
NCT01602822	TERMINATED	HIV	Kenneth H. Mayer, MD	2012-02	PHASE4
NCT02404259	COMPLETED	HIV	The HIV Netherlands Australia Thailand Research Collaboration	2010-06
NCT00896051	COMPLETED	HIV Infections; Acquired Immunodeficiency Syndrome	Janssen R&D Ireland	2009-08	PHASE2
NCT01475227	COMPLETED	HIV Infection	St Stephens Aids Trust	2011-12	PHASE4
NCT00931801	COMPLETED	HIV	Community Research Initiative of New England	2009-12	PHASE4
NCT00544128	COMPLETED	HIV Infections	International Medical Center of Japan	2007-10	PHASE4
NCT01194856	TERMINATED	HIV Infection; Mitochondrial Dysfunction	The Cleveland Clinic	2010-10	PHASE4
NCT01108510	COMPLETED	HIV; HIV Infections	Gilead Sciences	2010-04	PHASE3
NCT01591850	COMPLETED	Healthy Volunteer	Hoffmann-La Roche	2011-09	PHASE1
NCT00006604	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	2000-11	PHASE1; PHASE2
NCT01106586	COMPLETED	HIV; HIV Infections	Gilead Sciences	2010-04	PHASE3
NCT01404572	COMPLETED	HIV	Bristol-Myers Squibb	2011-08	PHASE1
NCT00874523	COMPLETED	HIV Infection	Kirby Institute	2009-07	PHASE3
NCT01232127	COMPLETED	HIV	Bristol-Myers Squibb	2011-02	PHASE4
NCT00756730	COMPLETED	HIV Infections	Community Research Initiative of New England	2008-09	PHASE4
NCT01458769	COMPLETED	Healthy Volunteers	Concert Pharmaceuticals	2010-12	PHASE1
NCT01928407	COMPLETED	HIV-1 Infection; Immunosuppression-related Infectious Disease	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	2011-02-23	PHASE4
NCT00335322	COMPLETED	Human Immunodeficiency Virus (HIV)	Kirby Institute	2007-02	PHASE4
NCT00389207	COMPLETED	HIV Infections	Boehringer Ingelheim	2006-10	PHASE3
NCT00869960	COMPLETED	Healthy	University of Alabama at Birmingham	2009-03	PHASE4
NCT00525239	UNKNOWN	HIV Infections	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2004-03
NCT00943540	COMPLETED	HIV Infection; HIV Infections	Radboud University Medical Center	2009-07	PHASE2
NCT00827112	COMPLETED	Human Immunodeficiency Virus-1	ViiV Healthcare	2009-03	PHASE2
NCT00440947	COMPLETED	Infection, Human Immunodeficiency Virus I; HIV Infection	ViiV Healthcare	2007-03	PHASE3
NCT00833482	COMPLETED	Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections	Bristol-Myers Squibb	2009-09	PHASE1
NCT01073761	COMPLETED	HIV; HIV Infections	St Stephens Aids Trust	2010-04	PHASE1
NCT00885482	COMPLETED	HIV Infections	Catholic University of the Sacred Heart	2009-05	PHASE4
NCT00084136	COMPLETED	HIV Infections	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	2005-05	PHASE4
NCT00916448	COMPLETED	Endotoxemia; Inflammation; Multi Organ Dysfunction Syndrome; Sepsis	Radboud University Medical Center	2009-05
NCT00552240	COMPLETED	HIV Infections	Boehringer Ingelheim	2007-09	PHASE4
NCT00242216	COMPLETED	HIV Infections	The University of Texas Health Science Center, Houston	2004-05	PHASE4
NCT00768989	TERMINATED	HIV	Bristol-Myers Squibb	2008-11	PHASE2
NCT00307502	COMPLETED	HIV Infections	Germans Trias i Pujol Hospital	2005-01	PHASE1
NCT01445223	COMPLETED	HIV	Göteborg University	2004-04	PHASE4
NCT00892437	COMPLETED	HIV-1 Infection	Gilead Sciences	2009-05	PHASE2
NCT00118898	COMPLETED	HIV Infections	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	2005-09	PHASE3
NCT00751153	UNKNOWN	HIV Infections	Peter J. Ruane, M.D., Inc.	2008-03	PHASE4
NCT00280969	COMPLETED	HIV Infection	International Medical Center of Japan	2005-09	PHASE3
NCT00385645	COMPLETED	HIV Infections	Hospital Clinic of Barcelona	2006-05	PHASE4
NCT00757783	COMPLETED	HIV	Tibotec, Inc	2008-10	PHASE4
NCT00883935	COMPLETED	Healthy Volunteer	GlaxoSmithKline	2009-04	PHASE1
NCT00260078	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	2006-02	PHASE1; PHASE2
NCT00696722	COMPLETED	Type 2 Diabetes Mellitus Related Endothelial Dysfunction	Radboud University Medical Center	2008-06	PHASE2
NCT00326716	COMPLETED	HIV Infection	Bristol-Myers Squibb	2006-06	PHASE1
NCT00718536	COMPLETED	HIV Infections	Germans Trias i Pujol Hospital	2008-08	PHASE4
NCT00413153	COMPLETED	HIV Infections	Massachusetts General Hospital	2006-05
NCT00528060	COMPLETED	HIV Infections	French National Agency for Research on AIDS and Viral Hepatitis	2008-01	PHASE2
NCT00646776	COMPLETED	Antivirals/HIV	Bristol-Myers Squibb	2008-04	PHASE1
NCT00225017	COMPLETED	HIV Infection; Hyperlipidemia	Northwestern University	2005-06	PHASE3
NCT01388543	COMPLETED	HIV	University of Colorado, Denver	2006-09	PHASE4
NCT00337467	COMPLETED	Human Immunodeficiency Virus (HIV) Infections	Bristol-Myers Squibb	2006-06	PHASE3
NCT00355719	COMPLETED	HIV Infections	Germans Trias i Pujol Hospital	2007-01	PHASE4
NCT00411957	COMPLETED	HIV Infections	The HIV Netherlands Australia Thailand Research Collaboration	2007-01	PHASE1; PHASE2
NCT00518297	COMPLETED	HIV Infections	Bristol-Myers Squibb	2007-08	PHASE1
NCT00384904	COMPLETED	HIV Infections	Bristol-Myers Squibb	2006-12	PHASE4
NCT00420355	TERMINATED	HIV Infection	University of Oklahoma	2007-04	PHASE4
NCT00207142	COMPLETED	HIV Infections	Bristol-Myers Squibb	2005-11	PHASE4
NCT00135356	COMPLETED	HIV-Associated Lipodystrophy Syndrome	Bristol-Myers Squibb	2005-07	PHASE4
NCT00272779	COMPLETED	HIV Infections	Bristol-Myers Squibb	2005-11	PHASE3
NCT00160329	COMPLETED	Hyperlipidemia; HIV Infections	Stanford University	2004-01	PHASE3
NCT00312754	TERMINATED	HIV Infections	Bristol-Myers Squibb	2005-06	PHASE4
NCT00224445	COMPLETED	HIV Infections	Gilead Sciences	2005-09	PHASE4
NCT00393328	COMPLETED	HIV Infections	Bristol-Myers Squibb	2006-11	PHASE1
NCT00362726	COMPLETED	HIV Infections	Bristol-Myers Squibb	2006-09	PHASE1
NCT00357604	COMPLETED	HIV Infections	Bristol-Myers Squibb	2006-07	PHASE1
NCT00720590	COMPLETED	Endothelial Dysfunction	Indiana University	2003-11
NCT00357188	COMPLETED	HIV Infections; Protease Inhibitor	Bristol-Myers Squibb	2006-07	PHASE1
NCT00357721	COMPLETED	HIV Infections; Protease Inhibitor	Bristol-Myers Squibb	2006-06	PHASE1
NCT00084253	COMPLETED	HIV Infections	Bristol-Myers Squibb	2004-06	PHASE4
NCT00357240	COMPLETED	HIV Infections	Bristol-Myers Squibb	2006-06	PHASE1
NCT00162149	COMPLETED	HIV Infections	Bristol-Myers Squibb	2005-10	PHASE1
NCT00365339	COMPLETED	HIV Infections	Bristol-Myers Squibb	2006-04	PHASE1
NCT00120393	COMPLETED	HIV Infections	Bristol-Myers Squibb	2004-01	PHASE3
NCT00192608	COMPLETED	HIV Infections	Kirby Institute	2004-11
NCT00082394	COMPLETED	Infection, Human Immunodeficiency Virus I; HIV Infection	GlaxoSmithKline	2004-04-26	PHASE4
NCT00135395	COMPLETED	HIV Infections	Bristol-Myers Squibb	2004-05	PHASE3
NCT00135343	COMPLETED	HIV Infections	Bristol-Myers Squibb	2004-04	PHASE3
NCT02253836	COMPLETED	Healthy	Boehringer Ingelheim	2005-01	PHASE1
NCT00135434	COMPLETED	HIV Infections	Bristol-Myers Squibb	2004-09	PHASE1
NCT00067782	COMPLETED	HIV Infections	Bristol-Myers Squibb	2002-12	PHASE3
NCT02257008	COMPLETED	Healthy	Boehringer Ingelheim	2003-03	PHASE1
NCT00028301	COMPLETED	HIV Infections	Bristol-Myers Squibb	2001-02	PHASE3
NCT00035932	COMPLETED	HIV Infections	Bristol-Myers Squibb	2001-11	PHASE3
NCT00013897	COMPLETED	HIV Infections	Bristol-Myers Squibb	2001-02	PHASE3
NCT00028067	TERMINATED	HIV Infections	Bristol-Myers Squibb	2001-08	PHASE3
NCT00004584	COMPLETED	HIV Infections	Bristol-Myers Squibb	1999-12	PHASE2
NCT00002240	COMPLETED	HIV Infections	Bristol-Myers Squibb	1999-03	PHASE2
NCT00028314	COMPLETED	HIV Infections; Lipodystrophy; Wasting Disease	National Institute of Allergy and Infectious Diseases (NIAID)	2002-03
NCT00122577	TERMINATED	HIV Infections	French National Agency for Research on AIDS and Viral Hepatitis	2002-03	PHASE2
NCT01368783	UNKNOWN	Atazanavir	Asan Medical Center	2011-06	PHASE1
NCT00007202	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)		PHASE2
NCT00013520	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)		PHASE3
NCT00447070	COMPLETED	HIV Infections; Dyslipidemia	Foundation for Cardiovascular Research, Zurich	2004-08	PHASE4
NCT00389402	COMPLETED	HIV Infections	International Antiviral Therapy Evaluation Center	2006-07	PHASE4
NCT00084019	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	2004-07
NCT00426296	UNKNOWN	HIV Infections; Lipodystrophy	Clinical Alliance for Research & Education - Infectious Diseases, LLC.	2006-08	PHASE4
NCT00096850	COMPLETED	HIV Infections; Tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)

(data from https://clinicaltrials.gov, updated on 2026-04-21)

Check the Atazanavir product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Atazanavir selectively binds to and inhibits the HIV-1 protease enzyme, thereby preventing the proteolytic cleavage of viral Gag and Gag-Pol polyprotein precursors into functional structural proteins and essential enzymes. This blockade disrupts mature virion assembly and renders newly produced viral particles immature and non-infectious, ultimately reducing viral load and providing therapeutic efficacy in the management of HIV-1 infection and AIDS.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).